tadocizumab
tadocizumab Basic information
- Product Name:
- tadocizumab
- Synonyms:
-
- tadocizumab
- Research Grade Tadocizumab (DHC33303)
- Research Grade Tadocizumab
- Tadocizumab (anti-Integrin α2β3)
- CAS:
- 339086-80-5
- MW:
- 0
- Mol File:
- Mol File
More
Less
tadocizumab Usage And Synthesis
Uses
Treatment of patients undergoing percutaneous coronary interventions.
in vivo
Tadocizumab (YM-337; C4G1) dose-dependently inhibits ex vivo platelet aggregation, with complete inhibition at doses higher than 0.25 mg/kg intravenous injection or 1.5 μg/kg/min infusion in rhesus monkeys[1].
Tadocizumab (YM-337; C4G1) at a dose of 1 mg/kg intravenous injection followed by 6 μg/kg/min infusion for 60 min prevented occlusive thrombus formation in monkeys, in a photochemically-induced thrombosis model in squirrel monkeys[1].
IC 50
GPIIb/IIIa
tadocizumabSupplier
Shanghai YuanYe Biotechnology Co., Ltd.
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
Wuhan Chemstan Biotechnology Co., Ltd.
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
TargetMol Chemicals Inc.
- Tel
- 4008200310
- marketing@tsbiochem.com
Biolab Reagents
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com